Published online Mar 21, 2015. doi: 10.3748/wjg.v21.i11.3361
Peer-review started: August 20, 2014
First decision: September 27, 2014
Revised: October 17, 2014
Accepted: December 16, 2014
Article in press: December 16, 2014
Published online: March 21, 2015
Core tip: Oral prescription medical foods are becoming part of the outpatient medical practice and are finding new uses as a therapeutic option for gastrointestinal disorders. This case series investigates the use of oral serum-derived bovine immunoglobulin/protein isolate (SBI) in the management of differing forms of irritable bowel syndrome (IBS). Because of the multifaceted mechanism of action, SBI provides a distinct protein source to normalize bowel function, gastrointestinal microbiota, and nutritionally enhance tight junction protein expression. As such, there may be potential use for patients with other forms of IBS besides IBS-D. Additional research is needed to explore this use.